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ABSTRACT
The primary objective of most gene expression
studies is the identification of one or more gene
signatures; lists of genes whose transcriptional
levels are uniquely associated with a specific bio-
logical phenotype. Whilst thousands of experimen-
tally derived gene signatures are published, their
potential value to the community is limited by their
computational inaccessibility. Gene signatures are
embedded in published article figures, tables or in
supplementary materials, and are frequently pre-
sented using non-standard gene or probeset
nomenclature. We present GeneSigDB (http://
compbio.dfci.harvard.edu/genesigdb) a manually
curated database of gene expression signatures.
GeneSigDB release 1.0 focuses on cancer and
stem cells gene signatures and was constructed
from more than 850 publications from which we
manually transcribed 575 gene signatures. Most
gene signatures (n=560) were successfully
mapped to the genome to extract standardized
lists of EnsEMBL gene identifiers. GeneSigDB
provides the original gene signature, the
standardized gene list and a fully traceable gene
mapping history for each gene from the original
transcribed data table through to the standardized
list of genes. The GeneSigDB web portal is easy to
search, allows users to compare their own gene list
to those in the database, and download gene
signatures in most common gene identifier formats.
INTRODUCTION
Microarray gene expression proﬁling and other high
throughput technologies have been applied to investigate
and classify thousands of biological conditions. Most
studies report one or more gene signatures; lists of genes
that are diﬀerentially regulated between the cellular states
under study, for example in a cell or tissue type, in
response to treatment or at a speciﬁc time point. The
value of these experimentally derived gene signatures
often extend beyond their initial publication. A range of
applications have been developed to use them, including
Gene Set Enrichment Analysis (GSEA) which analyzes
gene expression data to look for groups of genes (or
gene lists) over-represented among statistically signiﬁcant
genes from a particular experiment (1–3). In breast cancer,
a number of experimentally derived gene expression
signatures including Mammaprint and Oncotype DX
have been developed into commercial diagnostic assays
(4) and are being validated in large scale clinical trials
(5,6). Gene signatures are analyzed and validated on
new gene expression data (7,8) and novel computational
methods are being developed for meta analysis of gene
signatures. Finally, because published experimentally
derived gene signatures are typically selected to diﬀerenti-
ate between diﬀerent classes of samples, meta-analysis of
multiple gene lists may provide deeper insight into the
biological mechanisms underlying a wide range of
processes.
While public databases such as ArrayExpress and GEO
have been developed to capture gene expression data,
there is no existing resource to capture the valuable end-
product of the analysis of those data—the gene lists that
the analyses produce. Instead, these gene lists are often
included in tables or ﬁgures embedded in publications or
included as supplementary material on the journal’s
or the author’s website, making them generally inaccessi-
ble to automated computational analysis. If one is able to
access these lists, one often ﬁnds that the lists are reported
using non-standard gene identiﬁers, making comparison
to other lists, or often to the original data, a signiﬁcant
challenge. To be of maximal value, gene signatures should
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a common standard format that is computationally acces-
sible. In addition it should provide the original gene sig-
nature table as transcribed from the publication.
Reproduction of a computationally accessible original
transcribed gene signature table may provide additional
signature meta-data, such as information and annotation
about the experimental conditions and the criteria used in
generating gene lists from the data (such as t-statistics
scores or other ranking information) which is useful in
some gene set analyses.
There have been a number of attempts to collect exper-
imentally derived gene signatures, however these do not
generally retain the original transcribed gene signature
data from the publication. The largest collections of
gene signature are available in MSigDB (3). MSigDB
(v2.5) provides gene signatures as annotated lists of gene
symbols and have curated gene signatures from 344
publications. Curators and users can submit gene lists as
a two column table, containing a gene identiﬁer and its
gene symbol. However many MSigDB gene signatures
contain only gene symbols, thereby limiting their future
re-annotation. The Lists of Lists-Annotated (LOLA;
http://www.lola.gwu.edu) database (9) contains 47 gene
lists (v1.2, October 2009) and gene list input format is
limited to EntrezGene or Aﬀymetrix probeset identiﬁers.
SignatureDB (http://lymphochip.nih.gov/signaturedb/)
(10) provides 147 published and non-published gene
signatures related to haematopoietic cells. The number
of cancer gene signatures in Cancer Genes (http://cbio
.mskcc.org/cancergenes) (11) is 26, of which 4 are from
the published literature. The lack of retention of original
gene list identiﬁers by these resources, prevents remapping
of the original signatures as better genome assemblies
and annotation become available (12–14). Possibly due
to the limitations of the gene signature input formats,
frequently little or no information is provided on the
process used to map gene signatures to the identiﬁers
that are reported.
To address these issues and facilitate gene list meta-
analysis, we have systematically collected published gene
signatures from publications indexed in PubMed and
mapped them to a common, standardized format, and
have made these available in GeneSigDB (http://
compbio.dfci.harvard.edu/genesigdb). We do not collect
or re-analyze the gene expression data as this is being
done by other projects including gene expression atlas
(http://www.ebi.ac.uk/gxa). For the GeneSigDB initial
release, we reviewed over 850 published articles and
manually transcribed 575 experimental cancer gene
signatures from tables, ﬁgures or Supplementary Data
from 319 of those papers. Signatures were curated,
annotated, and mapped to the genome, providing 560
standardized gene lists. GeneSigDB provides both the
original transcribed gene signature as well as the gene
signature in a standard format and we publish a
mapping-trace showing how each gene identiﬁer in the
original signature was re-annotated. The GeneSigDB
web portal allows users to search for gene signatures
and provides tools to compare gene signatures, to
convert gene lists to common gene identiﬁers and
download gene signatures in over 30 diﬀerent gene iden-
tiﬁer formats.
COLLECTION AND CURATION OF GENE
SIGNATURES
Papers likely to contain one or more gene lists were ﬁrst
identiﬁed using PubMed searches of the form XXX AND
(‘genechip’ OR microarray OR ‘gene expression’) AND
(‘gene signature’ OR ‘gene list’ OR ‘expression proﬁle’
OR ‘Classiﬁer’ OR ‘Predictor’) AND English [la] NOT
Review [pt], where XXX represents terms relevant to the
particular search being conducted, such as ‘breast cancer’
or ‘stem cells.’ A full list of these terms is given in
Supplementary Table S1. GeneSigDBv1.0 is based on a
search of PubMed which was performed on 15 July 2009.
Each article was downloaded and gene signatures were
transcribed from the manuscript or its supplementary
materials. Information about the source and contents of
each gene signature (Tables 1 and 2) were captured into an
Excel spreadsheet template designed to capture gene
signatures and associated annotation. Gene signatures
appeared in a wide variety of places within particular
manuscripts, including tables and graphical or textual
ﬁgures (such as hierarchical clustering heatmaps) in the
primary manuscripts and in supplementary pdf, excel, or
text documents. Supplementary ﬁles appeared in a variety
of places, including websites maintained by journals and
on authors’ personal websites. Each gene signature was
given a signature identiﬁer (SigID) PMID-X, where
PMID is the PubMed identiﬁer of the article and X is
the table, ﬁgure or supplementary ﬁle number from
which the gene signature was extracted, for example
18490921-Table 3 indicates the gene signature was
Table 1. Gene Signature Metadata (GeneSigDB v1.0)
Name Description
PMID PubMed identiﬁer
Tissue Name of search term set used to search PubMed.
(Supplementary Table S1)
Organism Species common name (human, mouse, etc)
Platform Name of microarray or other experimental
technique used to derive gene signature (selection
from constrained list, Supplementary Data S2)
Platform
description
Description of platform
Genes article Number of genes in gene signature (as described
in the text of the article)
SigID Signature identiﬁer, in the format PMID-XXX,
where XXX is the gene signature table, ﬁgure
or supplementary ﬁle e.g. 18490921-Table 3
Sig name Name of gene signature, in the format
Tissue_AuthorYear_NumberofGenes
_Description. Description is optional. e.g. Breast
_Bertucci08_75genes
Sig
description
Description of gene signature, typically
extracted from table or ﬁgure legend (free text)
File
associated
Name of tab delimited ﬁle gene signature ﬁle.
Format is SigID.txt
URL URL from where gene signature was downloaded
Column
mappings
Content of each column in gene signature ﬁle
(selection from constrained list in Table 2)
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18490921 (15). Gene signatures were stored as tab-
delimited text ﬁles and named SigID.txt. Metadata
associated with each gene signature were extracted from
the Excel ﬁle and stored as an xml ﬁle, SigID-index.xml,
the elements of which are summarized in Figure 1 and
Tables 1 and 2. The XSD schema is available File 2 in
Supplementary Data. EnsEMBL gene identiﬁers were
used as the primary gene identiﬁer in standardized ﬁles
to allow gene signature comparisons within GeneSigDB.
All gene identiﬁers that could be mapped (listed in
Table 2) to the genome were extracted into a ﬁle named
SigID-mapping.txt (Figure 1) and were searched against
EnsEMBL (version 55, July 2009) using BioMart (Perl
API). The search history for each gene was saved in a
ﬁle called SigID-maptrace.txt. If multiple gene identiﬁers
successfully mapped to the genome, a hierarchal ranking
of identiﬁers was used to select the best gene match
(see online documentation for full description of
mapping process). Standardized gene lists were stored in
a ﬁle named SigID-standardized.txt. An individual direc-
tory was created for each PMID, which stored a PDF of
the source manuscript and the ﬁve ﬁles derived from the
gene signatures; SigID.txt, SigID-mapping.txt, SigID-
maptrace.txt, SigID-standardized.txt and SigID-
index.xml (Figure 1). These ﬁles are respectively, the
original gene signature, the mappable gene identiﬁers
from SigID.txt, the mapping-trace showing how each
gene was mapped, a list of EnsEMBL gene identiﬁers
that correspond to genes in SigID.txt, and xml annotation
of SigID.txt.
GeneSigDB RELEASE 1.0
The initial release of GeneSigDB provides 560 curated,
standardized gene signatures related to cancer of the
breast, ovary, lung, colon, skin, prostate, bladder,
endometrial, kidney, thyroid and gene signatures related
to stem cells (Tables 3 and 4). These are principally derived
from gene expression studies in human tumors and cell
lines (n=465) but also include additional signatures
from mouse (n=84) and rat (n=11) (Table 3). We
have curated a number of other species but have not pres-
ently mapped these to EnsEMBL genomes.
The number of gene signatures per tumor type
varies considerably (Table 4). Breast cancer which
has been subjected to extensive gene expression proﬁling
resulting in a new molecular subtype categorization
and commercial diagnostic signatures (4), has a high
number of gene signatures (n=238). There is also a
large number of gene signatures from stem cell research
(n=101), which are divided by those reported in studies
of human (n=52) and mouse (n=49) in GeneSigDB. But
in other ﬁelds of cancer research we have fewer gene
signatures (kidney n=6, endometrial n=8). The
average number of genes per signature across all gene
signatures is 81 genes. However, we see variation is the
number per tissue which again may reﬂect the ‘maturity’
of the analysis in a particular tumor. There is a broad
correlation between the average number of genes per
gene signature and the number of signatures collected
for that tumor.
Gene loss when mapping gene signatures
The lack of standardization in reporting gene lists,
and the continued evolution of the genome sequence and
its annotation cause some loss in mapping gene signatures
to standard identiﬁers. As can be seen in Table 5, many
published gene signatures do not provide probe identiﬁers
when reporting signatures despite the fact that the primary
identiﬁcation of the gene lists reported relies on the array
probes (or probesets) rather than the genes themselves.
Authors tend to report gene names or gene symbols
but rarely provide details on how the gene annotations
were obtained or the version of the database that
was used for mapping. The latter can be important as
some databases such as UniGene ‘retire’ cluster identiﬁers
or change the gene associated with a particular cluster and
Table 2. Column mappings (GeneSigDB v1.0)
Mapping element Description Mapping
ﬁle
a
Probe ID Platform speciﬁc identiﬁer Yes
b
Clone ID IMAGE clone identiﬁer Yes
c
GenBank ID GenBank accession number Yes
c
UniGene ID Unigene identiﬁer. Yes
EntrezGene ID EntrezGene or LocusLink identiﬁer Yes
Gene symbol HGNC oﬃcial gene symbol Yes
CCDS ID Consensus Coding Sequence
Database ID
Yes
EnsEMBL ID EnsEMBL gene ID Yes
RefSeq ID RefSeq gene identiﬁer Yes
Protein ID Protein sequence ID, SwissProt,
UniProt
No
Chromosome
map
Chromosomal localization data No
Geneset speciﬁc
factor
Factor or classiﬁer speciﬁc
to data,
character
No
Geneset speciﬁc
statistics
Fold change, Ranking of genes,
T-statistics,
correlation, p-value, numeric
No
Gene
description
Description or
title of gene
No
Other gene
description
KEGG, GO terms, Keywords, etc No
aYes indicates these columns were extracted to SigID-mapping.txt for
searching biomart.
bNot all platform Probe IDs are sequence mapped in biomart. For
some common unmapped microarrays, we sequence matched the
probe sequences to the genome. Others were ignored.
cGenBank EST and IMAGE clone ID sequences are not in EnsEMBL
and these were mapped via Unigene (See Methods).
Table 3. Number of articles processed and gene signatures extracted by
species
Human Mouse Rat Total
Publications 263 39 8 308
Gene signatures 465 84 11 560
Genes 14197 9755 773 –
Number of platforms 32 9 4 38
Average genes/signature 132 213 88 –
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can change associations as the genome sequence is reﬁned
over time. In 15 of 575 curated signatures, no mappable
gene identiﬁers were provided, the authors publish their
gene signature simply as a set of gene descriptions. In
Table 6, it can be seen that the success of mapping is
greatly aﬀected by the identiﬁer provided. One lesson
that clearly emerges from this analysis is that those
identiﬁers closest to the primary data, such as probe
identiﬁers, have the highest rate of mapping to the
EnsEMBL geneIDs that are our standard identiﬁers.
This failure in mapping severely limits our ability to
compare gene lists between studies, underscoring the
need for standardization in reporting gene lists.
Although in Table 6 it appears that there is a low
mapping success rate for EMBL/GenBank identiﬁers
(16% success), this is a subset of EMBL/GenBank
identiﬁers and this low mapping rate is an artifact of the
<?xml version="1.0"?> 
A
B
<signature xmlns="http://compbio.dfci.harvard.edu/genesigdb" 
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
 xsi:schemaLocation="http://compbio.dfci.harvard.edu/genesigdb 
GeneSigDB.xsd">
 <pmid>18490921</pmid> 
 <tissue>Breast</tissue> 
 <organism>Human</organism> 
 <platform> 
 <platformName>Custom cDNA Array</platformName> 
 </platform> 
 <genesArticle>75</genesArticle> 
 <fileAssociated>18490921-Table3.txt</fileAssociated> 
 <sigName>Breast_Bertucci08_75genes</sigName> 
 <sigDescription>75 -gene signature that discriminated Invasive lobular 
v invasive ductal breast cancer</sigDe 
scription>
 <sigID>18490921-Table3</sigID> 
<url>http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2008158a.h
tml</url>
 <columnMappings> 
 <column columnNumber="1">Gene Symbol</column> 
 <column columnNumber="2">Gene Description</column> 
 <column columnNumber="3">Clone ID</column> 
 <column columnNumber="4">GenBank ID</column> 
 <column columnNumber="5">UniGene ID</column> 
 <column columnNumber="6">RefSeq ID</column> 
 <column columnNumber="7">Other Gene Description</column> 
 <column columnNumber="8">Other Gene Description</column> 
 <column columnNumber="9">Chromosome Map</column> 
 <column columnNumber="10">Geneset Specific Factor</column> 
 </columnMappings> 
</signature>
Figure 1. Curation of gene signatures in GeneSigDB. (A) GeneSigDB hierarchical ﬁle structure SigID.txt, SigID-mapping.txt, SigID-maptrace.txt,
SigID-standardized.txt and SigID-index.xml. These ﬁles are respectively, the original gene signature, the mappable gene identiﬁers from SigID.txt, the
mapping-trace showing how each gene was mapped, a list of EnsEMBL gene identiﬁers that correspond to genes in SigID.txt, and xml annotation of
SigID.txt. (B) An example xml gene signature annotation ﬁle.
Nucleic Acids Research, 2010,Vol.38, Database issue D719Figure 2. Overlap in gene signatures across tumor types. (A) Heatmap-style representation of gene overlap. Each row is a gene and each column is a
tissue type. Presence of a gene is indicated by a black line, and absence is white. It can be seen that some gene maybe linked to phenotypic subclasses
in many tumors, but there are generally many more tumor-speciﬁc genes, likely indicating the eﬀect of the tissue of origin. (B) Dendrogram of
hierarchical cluster analysis that was performed using a Sorensen’s coeﬃcient asymmetrical measure of binary distance and joined using Ward’s
minimum variance method.
Table 4. Number of articles processed and gene signatures extracted by search terms (tissue)
Search terms Number of manuscripts (articles) Gene signatures Average of
genes
a
PubMed hits Downloaded
and processed
Curated Mapped Curated Mapped
to EnsEMBL
Bladder 64 56 10 10 18 18 115
Breast 471 241 134 131 243 238 190
Colon 95 54 20 20 35 35 84
Endometrial 15 15 5 4 9 8 16
Kidney 12 12 4 3 7 6 55
Liver 129 27 8 8 12 12 144
Lung 167 101 29 28 42 41 34
Ovary 108 72 28 28 41 41 75
Prostate 136 102 30 28 52 48 47
Skin 8 8 3 3 9 9 28
Stem cell 190 141 45 42 104 101 205
Thyroid 26 14 2 2 2 2 16
Uterus 54 8 1 1 1 1 45
Total 1475 851 319 308 575 560
aAverage number of genes per signature which were mapped to EnsEMBL genes.
D720 Nucleic AcidsResearch, 2010, Vol.38,Database issuesearch approach we are using that will be corrected in the
next release GeneSigDB.
Overlap in genes among gene signatures
Having assembled GeneSigDB, obvious questions are
which genes are most common in the various signatures
that have been reported and whether there is signiﬁcant
overlap between reported signatures in various cancers.
To analyze the overlap between gene signatures, the
union of all gene lists was compared to each individual
list to generate a binary matrix of presence (1) or absence
(0) calls of each gene in each gene list. GeneSigDB human
gene signatures (n=465) contain 14197 EnsEMBL genes.
Histograms showing the distribution of genes in human
and mouse gene signatures are provided File 3 in
Supplementary Data. A large number of genes only
occur in only 1 of 465 gene signatures (n=3611), and
10586 genes occur in 5 or fewer of the 465 gene signatures.
We used a simulation approach to estimate the number of
genes which might be in gene signatures by chance
(described File 3 in Supplementary Data) and excluded
low abundance genes. We investigated the overlap of the
remaining 9920 human genes across 465 gene signatures in
GeneSigDB. Figure 2 shows the overlap in gene content
across all gene signatures. It can clearly be seen that
related tumors such as breast and ovarian have a large
overlap relative to other tumor types. This may reﬂect
the fact that breast and ovarian cancers are known to
have some common genetic components, such as
mutations in the BRCA1 and BRCA2 genes. Figure 2b
shows a hierarchical clustering of genes in signatures that
was performed using a Sorensen’s coeﬃcient asymmetrical
measure of binary distance which gives double weight to
presence and ignores absence, as we assume that presence
of a gene in two lists is more informative than its absence
in two gene lists. An absent gene may not be truly absent;
gene expression platforms may not sample the entire
genome, the probes for a particular gene may be ineﬀec-
tive, or the applied feature selection approach may prove
sub-optimal. Since the gene x gene signature overlap
matrix is sparse, scoring a double-zero between two gene
lists would result in high similarity scores for many gene
lists containing only a few genes. In Figure 2b, we see
tumor types which are well represented in GeneSigDB
cluster apart from those for which we have fewer
numbers of gene signatures. However it is intriguing to
observe that breast, ovarian and stem cell, colon and
prostate signatures cluster, and this may reﬂect common
etiology in these cancers.
We investigated if there were genes that occur fre-
quently in many gene signatures. We observed 80 genes
occur in 25 or more gene signatures. The most frequently
observed genes occur in 50 of the 465 genes signatures and
are MAD2LI (ENSG00000164109) and RRM2
(ENSG00000171848). However, these occur predomina-
tely in breast genes signatures (n=42/50). We therefore
examined which genes are common in many tissues types
and observed 29 genes occur in 7 or more tissue types
(Table 7). We performed a representational analysis to
search Gene Ontology terms and KEGG pathways that
are over-represented in that set. Not surprisingly, the most
common functional classes found were those associated
with cell cycle, consistent with the fact that cancer is a
disease that disrupts normal cell cycle control (File 3 in
Supplementary Data).
THE GeneSigDB WEB INTERFACE
Querying GeneSigDB
There are two entry points into GeneSigDB, a
publication-based and a gene-based search. The publica-
tion search queries articles and retrieves a list of
publications and the signatures they describe. The results
are based on two independent searches. The ﬁrst is a full-
text search of the articles indexed in GeneSigDB. This
search includes the article title, authors, aﬃliations,
Table 6. Success of matching diﬀerent gene signature identiﬁers to an
EnsEMBL gene
ID type Species Success
(unique IDs)
Failures
(unique IDs)
Percentage
success
aﬀy_hg_u133_
plus_2
Human 11085 942 92
aﬀy_u133_x3p Human 180 10 94
aﬀy_hg_u133a Human 6384 288 95
aﬀy_hg_u95av2 Human 613 23 96
aﬀy_hg_u95a Human 25 2 92
aﬀy_hugeneﬂ Human 43 8 84
aﬀy_mouse430_2 Mouse 3816 195 95
aﬀy_moe430a Mouse 3409 159 95
aﬀy_mg_u74av2 Mouse 2156 317 87
aﬀy_mg_u74a Mouse 116 1 99
agilent_
wholegenome
Human,
mouse
3896 614 86
Entrezgene Human 9859 486 95
refseq_dna Human 5586 577 90
ensembl_gene_id Human 3120 486 86
hgnc_symbol Human 5254 2908 64
mgi_symbol Mouse 1247 788 61
rgd_symbol Rat 301 135 69
unigene Human,
mouse
2131 1865 53
embl (genbank) Human 308 1541 16
Table 5. Frequency of diﬀerent gene identiﬁers in mapped gene
signatures
Identiﬁer Frequency all
gene signatures
(n=560)
Frequency human
gene signatures
(n=465)
Gene description 476 381
Gene symbol 432 359
Probe ID 212 173
GenBank ID 128 109
UniGene ID 96 75
RefSeq ID 75 53
EntrezGene ID 49 39
Clone ID 30 26
EnsEMBL ID 11 9
Nucleic Acids Research, 2010,Vol.38, Database issue D721abstract, introduction, methods, results, discussion and
other items in the main body of the publication; the ref-
erence section is not included in this search. A second
search queries only the information indexed by PubMed
which includes title, author names, journal, title and
abstract. The most common publication search terms
would be an author name, article title, journal name or
keywords. Terms can be combined using standard
Boolean operators and examples are provided in the doc-
umentation online.
The gene search queries the annotation of genes within
indexed signatures. One can enter either a single gene or
multiple genes into the gene search. Gene search terms can
be gene symbols, EnsEMBL, Entrezgene, Aﬀymetrix,
Illumina or other common microarray probe identiﬁers.
A gene list can be entered in space or comma separated
format. Wildcard searches are permitted, for example
BRCA* will return BRCA1 and BRCA2 genes.
Examples of both publication and gene searches are
provided in the help documentation online.
GeneSigDB data views
There are three data views in GeneSigDB; a publication
view, a gene signature view, and a gene view. The ﬁrst is
the publication view which contains information about the
publication (authors, title, journal, publication date and
abstract) and links to all gene signatures extracted from
that publication. The second is the gene signature view
which presents the gene signature metadata (described in
Tables 1 and 2) and data related to the gene signature
(Figure 1), including the original transcribed gene signa-
ture table and a standardized gene list of EnsEMBL
identiﬁers and gene symbols. GeneSigDB also provides a
history of how each gene was mapped to EnsEMBL.
When a gene cannot be mapping to an EnsEMBL gene,
this is clearly stated. The third data view is the gene view,
which provides gene annotation information such as gene
synonyms, description and gene identiﬁers of popular
databases (EnsEMBL, EntrezGene, RefSeq). Where a
gene signature is of non-human origin, the human
orthologue of the gene is provided (where possible). A
gene view lists all gene signatures in which that gene can
be found.
Visualization of overlap between gene signatures
To visualize the overlap between multiple gene signatures,
one can tick checkboxes selecting multiple gene signatures
in several views including the publication search results,
gene search results, or gene or publication entry view.
These gene signatures are passed to a gene signature com-
parison view. This opens a genesignature comparison
matrix in which the rows are genes and the columns are
Table 7. Most common genes across genes signatures from all tissue types
EnsEMBL Gene ID Hgnc symbol Number
tissue types
Counts of gene signatures in tissue types
Bld Br Co End Kd Li Lu Ov Pr Sk SC Thy Ut
ENSG00000113140 SPARC 9 2 24 2 0 0 1 2 3 1 3 1 0 0
ENSG00000115414 FN1 8 1 22 1 0 0 2 1 7 5 0 2 0 0
ENSG00000131747 TOP2A 8 0 30 1 0 1 1 1 3 2 0 4 0 0
ENSG00000134755 DSC2 8 0 8 1 0 1 1 1 1 1 0 1 0 0
ENSG00000151914 DST 8 0 15 2 0 0 1 1 1 1 2 3 0 0
ENSG00000157456 CCNB2 8 0 27 1 0 1 0 2 2 1 0 2 1 0
ENSG00000134057 CCNB1 8 0 22 1 1 0 0 3 1 3 1 2 0 0
ENSG00000087586 AURKA 8 0 33 1 2 1 0 0 1 1 1 4 0 0
ENSG00000120992 LYPLA1 8 1 6 1 1 0 1 1 0 1 0 2 0 0
ENSG00000132646 PCNA 7 1 19 2 0 0 0 2 3 2 0 1 0 0
ENSG00000169429 IL8 7 2 14 3 0 0 0 1 3 2 0 2 0 0
ENSG00000121966 CXCR4 7 1 16 1 0 0 0 0 1 1 1 3 0 0
ENSG00000139318 DUSP6 7 0 11 1 0 0 2 1 1 1 0 2 0 0
ENSG00000146674 IGFBP3 7 0 8 2 0 0 1 1 4 3 0 1 0 0
ENSG00000170312 CDC2 7 0 28 1 1 0 0 2 1 2 0 4 0 0
ENSG00000185275 CD24L4 7 0 15 1 1 0 0 1 1 1 0 2 0 0
ENSG00000164171 ITGA2 7 0 5 1 0 1 1 0 1 2 0 2 0 0
ENSG00000176890 TYMS 7 1 17 2 0 0 1 1 2 0 0 2 0 0
ENSG00000044115 CTNNA1 7 1 8 1 0 0 0 1 1 0 1 1 0 0
ENSG00000164442 CITED2 7 3 10 2 1 0 0 1 2 0 0 1 0 0
ENSG00000003436 TFPI 7 0 10 1 0 1 1 0 1 0 2 1 0 0
ENSG00000108821 COL1A1 7 1 15 0 0 0 1 4 1 1 0 4 0 0
ENSG00000111348 ARHGDIB 7 1 10 0 0 0 3 2 1 1 0 1 0 0
ENSG00000196139 AKR1C3 7 1 5 0 0 0 1 1 1 1 0 3 0 0
ENSG00000204262 COL5A2 7 1 13 0 0 0 0 2 2 1 2 1 0 0
ENSG00000142871 CYR61 7 1 11 0 0 0 1 0 1 4 1 2 0 0
ENSG00000170345 FOS 7 1 24 0 0 0 1 0 1 5 0 2 0 1
ENSG00000167642 SPINT2 7 0 7 0 0 1 0 1 1 2 1 1 0 0
ENSG00000175063 UBE2C 7 0 25 0 0 1 0 1 2 1 0 1 1 0
Tissue types are Bladder (Bld), Breast (Br), Colon (Co), Endometrial (End), Kidney (Kd), Liver (Li), Lung (Lu), Ovary (Ov), Prostate (Pr), Skin
(Sk), Stem Cell (SC), Thyroid (Thy), Uterus (Ut).
D722 Nucleic AcidsResearch, 2010, Vol.38,Database issuesignatures; the elements of the matrix are colored
heatmap-style red or grey to represent presence or
absence respectively. The default setting is that only
genes present in two or more signatures are shown. As
an example, Figure 3 shows the overlap of Fanconi
anemia associated genes in GeneSigDB gene signatures.
This analysis is based on a gene search with the wild
card search FANC* which returned 12 human genes and
2 mouse genes. We selected the 12 human genes by ticking
the checkboxes and then clicked on the compare button to
visualize the overlap in these in the comparison view.
Downloading gene signatures
In the publication search results, gene search results or
gene or publication entry view, gene signatures can be
selected for download using checkboxes which are
passed to a download page. There, a user can choose to
download the standard gene list (EnsEMBL gene
identiﬁers and gene symbols) or can choose to convert
gene signatures into one or many commonly used
identiﬁers, including Entrezgene, ReqSeq gene identiﬁers
or Aﬀymetrix, Agilent or Illumina probe identiﬁers. There
is no limit to the number of identiﬁers that can be selected
or to the number of gene signatures that can be
downloaded concurrently. Each gene signature is
provided in a separate comma separated ﬁle and if
multiple gene signatures are downloaded together, these
are compressed into one zip ﬁle.
Architecture of Web interface to GeneSigDB
The web interface to GeneSigDB (http://compbio.dfci
.harvard.edu/genesigdb) is based on HTML, CSS, JSP,
XML and Java 1.6 technologies. The application runs
on an Apache Tomcat 6 web application server running
on a CentOS 5 Linux server. Front-end interactivity
makes use of the jQuery 1.3.2 Javascript library and
server-side processing is based on the Apache Lucene 2.0
framework. GeneSigDB is not based on traditional
database technology since the application does not
require a high level of read/write access. Instead, the full
text of articles along with numerous other curated
resources are indexed and cross-referenced using the
Lucene model (http://lucene.apache.org/) to produce a
high-performance search system.
Comparison of GeneSigDB to other gene signature
resources
GeneSigDB provides a large collection of experimentally
derived gene signatures. To the best of our knowledge,
only MSigDB contains more curated gene signatures.
Figure 3. Visualization of gene overlap in gene signatures. In this example, we searched for Fanconi anemia-related genes by performing a gene
search for FANC* which returned 12 human genes and 2 mouse genes. This screen shows the overlap between gene signatures in which these 12
genes are present in at least 2/12. Red and grey boxes indicate presence or absence, respectively.
Nucleic Acids Research, 2010,Vol.38, Database issue D723MSigDB contains 1186 curated (c2) gene signatures from
344 publications, however the overlap between MSigDB
and GeneSigDB is minimal. Only signatures from 13
publications are contained in both MSigDB and
GeneSigDB. Consequently GeneSigDB release 1.0
provides a large number of cancer and stem cell gene
signatures that were not previously computationally
accessible.
One fundamental aspect of GeneSigDB that diﬀers
from existing resources is the importance given to
traceability of each gene signature. Each gene signature
has a signature identiﬁer PMID-X, where PMID is the
PubMed identiﬁer of the article and X is the table,
ﬁgure or supplementary ﬁle number from which the gene
signature was extracted, so that it can be easily traced
to the original publication. In addition we provide a
transcribed copy of the original table from the article.
A fully traceable gene history for each gene from the
original transcribed data table through to the
standardized list of genes is also provided, including
version number of all databases used in generating gene
annotation. Therefore the source gene of identiﬁers in
each standardized gene list should be unambiguous.
Since original gene identiﬁers are stored and formatted
in an annotation pipeline, GeneSigDB standardized gene
lists and annotation will be updated with each release of
GeneSigDB.
SUMMARY AND FUTURE DIRECTIONS
GeneSigDB ﬁlls an important need within the commu-
nity—the need to standardize gene expression signatures
to facilitate comparison and to allow them to be easily
queried and used in other analyses. GeneSigDB release
v1.0 focused on cancer and stem cell gene signatures
because these together represent some of the largest
sources of gene expression-based signatures. Because of
the way in which these signatures were identiﬁed, we antic-
ipate that they may capture many of the underlying pro-
cesses associated with the development and progression of
cancers and that their comparison may yield additional
insight into the disease. We also recognize that many of
these processes likely are important in other disease and
non-disease phenotypes. Consequently, we plan to expand
GeneSigDB to include a broader range of gene signatures,
both from other disease-based studies and signatures
arising from diﬀerent technologies such as copy number
variation arrays. The GeneSigDB web site interface will
continue to improve and we intend to implement several
new features that will vastly improve the gene signature
comparison visualization. We are also working to expand
gene signature annotation in GenSigDB to provide web
links to GEO or ArrayExpress datasets (where applica-
ble), and biological sample information on the source of
each gene signature, and in future also hope to implement
a controlled vocabulary to enable better searching and
analysis of gene signatures.
One lesson that we have learned from GeneSigDB is
that there is a pressing need for standardization of gene
expression signatures. Our creation of this database grew
out of a desire to do a simple computational analysis of
published gene expression signatures to look for
similarities between tumors arising in diﬀerent organ
sites. While databases such as ArrayExpress and GEO
have become valuable repositories for the raw data from
expression studies, the gene expression signatures that are
the results of expert analysis of those data are currently
not stored or reported in a systematic fashion. While
GeneSigDB represents an attempt to remedy the situation,
the need for extensive manual assembly and curation
argues for the development of standardized reporting
formats for gene signatures to facilitate their broader use
and reuse.
LICENSE
The software used in constructing GeneSigDB is open
source software and provided under the Artistic License.
All content within GeneSigDB is provided without
restriction.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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